Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Clinical management of BRCA1 and BRCA2 mutation carriers

Abstract

The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary site-specific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management at women with a strong family history of these diseases. Here, we review the current evidence for risk reduction strategies and outline future research directions.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H et al. (2004). JAMA 291: 1701–1712.

  • Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC et al. (2006). J Natl Cancer Inst 98: 535–544.

  • Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al. (2003). Am J Hum Genet 72: 1117–1130.

  • Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J et al. (2001). Gynecol Oncol 80: 341–345.

  • Beral V . (2003). Lancet 362: 419–427.

  • Beral V, Bull D, Reeves G . (2005). Lancet 365: 1543–1551.

  • Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL . (2002). J Natl Cancer Inst 94: 1365–1372.

  • Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V et al. (2004). Int J Gynecol Pathol 23: 35–40.

  • Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT . (2005). Gynecol Oncol 97: 457–467.

  • Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY . (2003). Cancer 97: 2187–2195.

  • Colgan TJ, Boerner SL, Murphy J, Cole DE, Narod S, Rosen B . (2002). Gynecol Oncol 85: 397–403.

  • Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B . (2001). Am J Surg Pathol 25: 1283–1289.

  • D'Andrea AD, Grompe M . (2003). Nat Rev Cancer 3: 23–34.

  • Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C et al. (2006). Lancet Oncol 7: 223–229.

  • Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K et al. (2005). J Clin Oncol 23: 7491–7496.

  • Eitan R, Soslow R, Lin O, Kauff ND, Liu L, Barakat RR et al. (2006). Gynecol Oncol 102: 315–318.

  • Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. (2005). Nature 434: 917–921.

  • Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A et al. (2005). J Natl Cancer Inst 97: 1652–1662.

  • Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al. (1998). J Natl Cancer Inst 90: 1371–1388.

  • Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE . (1994). Lancet 343: 692–695.

  • Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL et al. (2006). Breast Cancer Res 8: R15.

  • Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D . (1995). Obstet Gynecol 85: 304–313.

  • Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M et al. (2006). Int J Cancer 118: 2281–2284.

  • Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC et al. (2002). Lancet 359: 1471–1477.

  • Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG et al. (1999). N Engl J Med 340: 77–84.

  • Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL et al. (2001). J Natl Cancer Inst 93: 1633–1637.

  • Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C et al. (2002). Science 297: 606–609. Epub 2002 Jun 13.

  • Jernstrom H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C et al. (2004). J Natl Cancer Inst 96: 1094–1098.

  • Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA et al. (2002). N Engl J Med 346: 1609–1615.

  • Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP . (2004). J Natl Cancer Inst 96: 1659–1668.

  • King MC, Marks JH, Mandell JB . (2003). Science 302: 643–646.

  • King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K et al. (2001). Jama 286: 2251–2256.

  • Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH . (2005). J Clin Oncol 23: 8629–8635.

  • Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM et al. (2004). N Engl J Med 351: 427–437.

  • Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ et al. (1998). J Natl Cancer Inst 90: 1138–1145.

  • Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S et al. (2005). Clin Cancer Res 11: 5175–5180.

  • Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L et al. (2002). J Clin Oncol 20: 2310–2318.

  • Lavie O, Hornreich G, Ben-Arie A, Rennert G, Cohen Y, Keidar R et al. (2004). Gynecol Oncol 92: 521–524.

  • Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG et al. (2005). Lancet 365: 1769–1778.

  • Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D et al. (2000). J Clin Oncol 18: 2728–2732.

  • McEwen AR, McConnell DT, Kenwright DN, Gaskell DJ, Cherry A, Kidd AM . (2004). Gynecol Oncol 92: 992–994.

  • Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB et al. (2001). N Engl J Med 345: 159–164.

  • Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A et al. (2005). Cancer Epidemiol Biomarkers Prev 14: 350–356.

  • Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U et al. (2001). N Engl J Med 345: 235–240.

  • Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL et al. (2000). Lancet 356: 1876–1881.

  • Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P et al. (2002). J Natl Cancer Inst 94: 1773–1779.

  • Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD et al. (2006). Lancet Oncol 7: 402–406.

  • Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H et al. (1998). N Engl J Med 339: 424–428.

  • Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ et al. (2006). J Clin Oncol 24: 2437–2443.

  • Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L et al. (2000). J Clin Oncol 18: 3360–3369.

  • Piver MS, Jishi MF, Tsukada Y, Nava G . (1993). Cancer 71: 2751–2755.

  • Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C et al. (2005). J Clin Oncol 23: 127–132.

  • Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE et al. (2004). J Clin Oncol 22: 1055–1062. E-pub 23 February 2004.

  • Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB et al. (2005). J Clin Oncol 23: 7804–7810. E-pub 11 October 2005.

  • Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L et al. (1999). J Natl Cancer Inst 91: 1475–1479.

  • Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE et al. (2002). N Engl J Med 346: 1616–1622.

  • Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. (2002). JAMA 288: 321–333.

  • Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S et al. (2003). J Natl Cancer Inst 95: 1072–1078.

  • Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N et al. (1996). J Natl Cancer Inst 88: 1810–1820.

  • Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T et al. (2004). J Clin Oncol 22: 1823–1829. E-pub 5 April 2004.

  • The Breast Cancer Linkage Consortium (1999). J Natl Cancer Inst 91: 1310–1316.

  • Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H et al. (2003). Nat Med 9: 568–574.

  • Thompson D, Easton DF . (2002). J Natl Cancer Inst 94: 1358–1365.

  • Venkitaraman AR . (2002). Cell 108: 171–182.

  • Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA et al. (2004). JAMA 292: 1317–1325.

  • Whittemore AS, Balise RR, Pharoah PD, Dicioccio RA, Oakley-Girvan I, Ramus SJ et al. (2004). Br J Cancer 91: 1911–1915.

Download references

Acknowledgements

This work was supported by the Marjorie B Cohen Foundation and the US Department of Defense (DAMD-17-03-1-0619 to SMD).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S M Domchek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Domchek, S., Weber, B. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25, 5825–5831 (2006). https://doi.org/10.1038/sj.onc.1209881

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209881

Keywords

This article is cited by

Search

Quick links